Home › Companies › Axsome Therapeutics, Inc. › 2025-2026

Axsome Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Axsome Therapeutics, Inc.’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.

4Ballot items
410Asset managers
1,895Fund votes
June 5, 2026Meeting date

Results at a glance

Meeting of June 5, 2026: 4 items on Axsome Therapeutics, Inc.’s Form 8-K, filed June 9, 2026: 2 elected · 2 approved.

Material dissent

Elect Director: Mark Saad 74% of votes cast Elected Director under 80%
Elect Director: Susan Mahony, Ph.D., MBA 77% of votes cast Elected Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Axsome Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Axsome Therapeutics, Inc.

These tallies are Axsome Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Axsome Therapeutics, Inc. — official shareholder meeting results, meeting held June 5, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Mark Saad	28,675,654	--	--	10,286,822	4,815,060	74%	Elected	—
Elect Director: Susan Mahony, Ph.D., MBA	29,892,131	--	--	9,070,345	4,815,060	77%	Elected	—
2. Ratification of Appointment of Deloitte & Touche LLP	43,278,147	14,407	484,982	--	0	99.9%	Approved	—
3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers	37,818,384	777,937	366,155	--	4,815,060	98%	Approved	—

Source: Axsome Therapeutics, Inc., Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.

How asset managers voted at the Axsome Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 410 asset managers that disclosed a Axsome Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Mark Saad

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD

FOR: 28,675,654WITHHELD: 10,286,822

Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: Election of Directors: Mark Saad

Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Mark Saad”): 28,675,654 for, 10,286,822 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 12,163,702 for, 3,743,159 withheld, 396,743 abstained, 50 not voted.

FORWITHHOLD

FOR: 12,163,702ABSTAIN: 396,743WITHHOLD: 3,743,159NOT VOTED: 50

Largest asset managers voting on “Election of Directors: Mark Saad” at Axsome Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,261,231	33	18,661	For
Fidelity	2,528,128	0	13,900	For
BlackRock	2,051,700	0	0	For
T. Rowe Price	0	0	931,652	Withhold
Invesco	853,953	0	0	For
First Trust	0	0	561,179	Withhold
MUTUAL FUND SERIES TRUST	496,558	0	6,438	For
Delaware/Macquarie	0	0	444,493	Withhold
Charles Schwab	393,406	0	110	For
TIAA	0	0	252,697	Withhold
Jackson National	212,271	32,776	0	Mixed
Putnam	190,657	0	0	For
Principal	0	0	169,495	Withhold
Manager Directed Portfolios	168,240	0	0	For
Brighthouse	81,393	0	83,311	Mixed
Columbia Threadneedle	0	0	153,831	Withhold
John Hancock	11,796	137,462	0	Mixed
Loomis Sayles	0	139,821	0	Abstain
Franklin Custodian Funds	0	0	128,461	Withhold
Voya	0	0	116,066	Withhold
Waddell & Reed	0	0	103,315	Withhold
Royce	93,662	0	0	For
Equitable	58,901	0	34,249	Mixed
Hartford	91,430	0	0	For
Nuveen	0	0	76,149	Withhold

Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.

2. Elect Director: Susan Mahony, Ph.D., MBA

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD

FOR: 29,892,131WITHHELD: 9,070,345

Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: Election of Directors: Susan Mahony, Ph.D., MBA

Axsome Therapeutics, Inc.’s own tally for this item (“Elect Director: Susan Mahony, Ph.D., MBA”): 29,892,131 for, 9,070,345 withheld, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders elected the following directors to serve as Class II directors until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 12,437,850 for, 3,469,184 withheld, 396,570 abstained, 50 not voted.

FORWITHHOLD

FOR: 12,437,850ABSTAIN: 396,570WITHHOLD: 3,469,184NOT VOTED: 50

Largest asset managers voting on “Election of Directors: Susan Mahony, Ph.D., MBA” at Axsome Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,263,496	29	16,400	For
Fidelity	2,528,128	0	13,900	For
BlackRock	2,051,700	0	0	For
T. Rowe Price	0	0	931,652	Withhold
Invesco	853,953	0	0	For
First Trust	0	0	561,179	Withhold
MUTUAL FUND SERIES TRUST	496,558	0	6,438	For
Delaware/Macquarie	0	0	444,493	Withhold
Charles Schwab	393,516	0	0	For
TIAA	0	0	252,697	Withhold
Jackson National	212,271	32,776	0	Mixed
Putnam	190,657	0	0	For
Principal	0	0	169,495	Withhold
Manager Directed Portfolios	168,240	0	0	For
Brighthouse	81,393	0	83,311	Mixed
Columbia Threadneedle	153,831	0	0	For
John Hancock	11,796	137,462	0	Mixed
Loomis Sayles	0	139,821	0	Abstain
Franklin Custodian Funds	0	0	128,461	Withhold
Voya	0	0	116,066	Withhold
Waddell & Reed	0	0	103,315	Withhold
Royce	93,662	0	0	For
Equitable	58,901	0	34,249	Mixed
Hartford	91,430	0	0	For
Nuveen	0	0	76,149	Withhold

Showing the 25 largest of 104 asset managers. See all 104 in the interactive database.

3. 3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%

FOR: 37,818,384AGAINST: 777,937

Details: description as filed, official tally, votes by 409 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers.

Axsome Therapeutics, Inc.’s own tally for this item (“3. Approval, by Non-Binding Advisory Vote, of the Compensation of the Company's Named Executive Officers”): 37,818,384 for, 777,937 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 103 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at Axsome Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	4,279,922	3	1	For
Fidelity	2,542,028	0	0	For
BlackRock	2,051,700	0	0	For
T. Rowe Price	931,652	0	0	For
Invesco	853,953	0	0	For
First Trust	561,179	0	0	For
MUTUAL FUND SERIES TRUST	502,996	0	0	For
Delaware/Macquarie	444,493	0	0	For
Charles Schwab	393,516	0	0	For
TIAA	252,697	0	0	For
Jackson National	245,047	0	0	For
Putnam	190,657	0	0	For
Principal	169,495	0	0	For
Manager Directed Portfolios	168,240	0	0	For
Brighthouse	161,116	0	3,588	For
Columbia Threadneedle	153,831	0	0	For
John Hancock	149,258	0	0	For
Loomis Sayles	139,821	0	0	For
Franklin Custodian Funds	128,461	0	0	For
Voya	116,066	0	0	For
Waddell & Reed	103,315	0	0	For
RBB FUND, INC.	97,977	0	0	For
Royce	93,662	0	0	For
Equitable	93,150	0	0	For
Hartford	91,430	0	0	For

Fund voting reports, all 103 managers: 16,345,560 for, 5,246 against, 3,589 abstained, 50 not voted, 94 mixed. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 336 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers.” at Axsome Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	1,646,603	0	For
BlackRock	1,606,751	8,809	For
Invesco	1,528,689	0	For
T. Rowe Price	1,409,788	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,163,544	0	For
State Street	888,250	1,327	For
Wellington	839,000	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	737,578	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	702,773	0	For
Charles Schwab	395,169	0	For
PICTET ASSET MANAGEMENT SA	369,389	0	For
Northern Trust	360,749	2,848	For
Vanguard	358,026	0	For
Nuveen	335,760	0	For
Hood River Capital Management LLC	311,038	0	For
Putnam	285,361	0	For
Citadel	266,615	0	For
Loomis Sayles	247,919	0	For
PRINCIPAL GLOBAL INVESTORS	233,446	0	For
ORBIMED ADVISORS LLC	213,921	0	For
PNC BANK, NATIONAL ASSOCIATION	201,048	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	200,357	0	For
Point72	199,671	0	For
DE Shaw	186,859	0	For
MELLON INVESTMENTS Corp	171,139	0	For

Institutional-manager reports, all 336 managers: 19,105,376 for, 358,174 against, 5,429 abstained, 873 not voted. Showing the 25 largest; see all in the interactive database.

4. 2. Ratification of Appointment of Deloitte & Touche LLP

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%

FOR: 43,278,147AGAINST: 14,407

Details: description as filed, official tally, votes by 103 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

Axsome Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of Deloitte & Touche LLP”): 43,278,147 for, 14,407 against — passed, per its Form 8-K filed June 9, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 103 asset managers below reported 16,295,166 for, 3,588 abstained, 50 not voted.

FOR

FOR: 16,295,166ABSTAIN: 3,588NOT VOTED: 50

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING F” at Axsome Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	4,279,925	0	For
Fidelity	2,542,028	0	For
BlackRock	2,051,700	0	For
T. Rowe Price	931,652	0	For
Invesco	853,953	0	For
First Trust	561,179	0	For
MUTUAL FUND SERIES TRUST	502,996	0	For
Delaware/Macquarie	444,493	0	For
Charles Schwab	393,516	0	For
TIAA	252,697	0	For
Jackson National	245,047	0	For
Putnam	190,657	0	For
Principal	169,495	0	For
Manager Directed Portfolios	168,240	0	For
Brighthouse	161,116	3,588	For
Columbia Threadneedle	153,831	0	For
John Hancock	149,258	0	For
Loomis Sayles	139,821	0	For
Franklin Custodian Funds	128,461	0	For
Voya	116,066	0	For
Waddell & Reed	103,315	0	For
Royce	93,662	0	For
Equitable	93,150	0	For
Hartford	91,430	0	For
Nuveen	76,149	0	For

Showing the 25 largest of 103 asset managers. See all 103 in the interactive database.

Largest Axsome Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,459,766 shares outstanding at the time of that meeting.

Fund voting reports: top Axsome Therapeutics, Inc. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	8.32%
2	Fidelity	4.94%
3	BlackRock	3.99%
4	T. Rowe Price	1.81%
5	Invesco	1.66%
6	First Trust	1.09%
7	MUTUAL FUND SERIES TRUST	0.98%
8	Delaware/Macquarie	0.86%
9	Charles Schwab	0.76%
10	TIAA	0.49%

Institutional-manager reports: top Axsome Therapeutics, Inc. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	3.20%
2	BlackRock	3.14%
3	Invesco	2.97%
4	T. Rowe Price	2.74%
5	GEODE CAPITAL MANAGEMENT, LLC	2.26%
6	State Street	1.73%
7	Wellington	1.63%
8	ADAGE CAPITAL PARTNERS GP, L.L.C.	1.43%
9	NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	1.37%
10	Charles Schwab	0.77%

Reported Axsome Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Axsome Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Herriot Tabuteau, M.D.	17.47%	DEF14A
Antecip Capital LLC	14.27%	DEF14A
Vanguard Group	8.09%	13F
BlackRock	7.60%	13F
FMR (Fidelity)	3.05%	13F
T. Rowe Price	2.56%	13F
Invesco	2.52%	13F
Geode Capital	2.26%	13F
Wellington Management	2.23%	13F
State Street	1.92%	13F

Percentages above are of 51,459,766 shares outstanding, as reported by Axsome Therapeutics, Inc. on its Form 10-Q dated April 27, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Axsome Therapeutics, Inc.’s 10-Q dated April 27, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Axsome Therapeutics, Inc.'s shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 410 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,895 separate fund positions. On the most widely held item on that ballot — To approve, by non-binding advisory vote, the compensation of our named executive officers. — Axsome Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Axsome Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.

Axsome Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.